>   Structural Summary
100% seqID Fv Structure5ggu [Fvs: AB, HL], 5ggv [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
Highest Clinical Trial (October '21)Phase-III
Estimated Status (October '21)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2005
INN Year Recommended2008
Companies InvolvedAIO Studien gGmbH, Amgen, ARCAGY/GINECO Group, AstraZeneca, Azienda Ospedaliera Universitaria Senese, Canadian Cancer Trials Group, Charite - Universitatsmedizin Berlin, Dana-Farber Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Grupo Espanol de Tumores Neuroendocrinos, Hoosier Cancer Research Network, Immunocore, Institute Gustave-Roussy, Kyoto Breast Cancer Research Network, M. D. Anderson Cancer Center, MedImmune, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), Northwestern University, Pfizer, Seoul National University Hospital, UNICANCER, University College London, University of Maryland Greenbaum Cancer Center, Yonsei University College of Medicine
Conditions Approvedna
Conditions ActiveHead and neck cancer, Liver cancer, Mesothelioma, Non-small cell lung cancer, Renal cell carcinoma, Small cell lung cancer, Solid tumours, Urogenital cancer, Biliary cancer, Bladder cancer, Breast cancer, Cholangiocarcinoma, Colorectal cancer, Endometrial cancer, Fallopian tube cancer, Gallbladder cancer, Gastric cancer, Gastrointestinal cancer, Germ cell and embryonal neoplasms, Glioblastoma, Lung cancer, Neuroendocrine tumours, Oropharyngeal cancer, Ovarian cancer, Pancreatic cancer, Peritoneal cancer, Prostate cancer, Sarcoma, Soft tissue sarcoma, Thyroid cancer, Haematological malignancies, Malignant melanoma, Oesophageal cancer, Cervical cancer
Conditions DiscontinuedDiffuse large B-cell lymphoma, Gynaecological cancer, Myelodysplastic syndromes
NotesTremelimumab is the new name for Ticilimumab (PL97)

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy